Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma

Hepatology

Volumn 58, Issue 3, 2013, Pages 1031-1041

  Gürlevik, Engin ^a   Fleischmann Mundt, Bettina ^a   Armbrecht, Nina ^a   Longerich, Thomas ^b   Woller, Norman ^a   Kloos, Arnold ^a   Hoffmann, Dirk ^a   Schambach, Axel ^a   Wirth, Thomas C ^a   Manns, Michael P ^a   Zender, Lars ^c   Kubicka, Stefan ^a,d   Kühnel, Florian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d District Hospital Reutlingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; K RAS PROTEIN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMATOSIS; CELL TRANSDIFFERENTIATION; LIVER; LIVER CELL; LUNG METASTASIS; METASTASIS; METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA; MOUSE; NONHUMAN; PLASMID; PRIMARY TUMOR; PRIORITY JOURNAL; TRANSPOSON; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; HEPATECTOMY; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS P21(RAS); RISK FACTORS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883225973     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26468     Document Type: Article

References (39)

1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357.
2. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620-626.
3. Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 2008;207:594-603.
4. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010;42:253-260.
5. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42.
6. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531-3540.
7. Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002;8:3156-3163.
8. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000;47:721-727.
9. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006;66:6622-6627.
10. O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 2012;72:1557-1567.
11. Sempoux C, Fan C, Singh P, Obeidat K, Roayaie S, Schwartz M, et al. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis 2011;31:104-110.
12. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012;122:2911-2915.
13. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest 2012;122:3914-3918.
14. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-184.
15. Puhalla H, Schuell B, Pokorny H, Kornek GV, Scheithauer W, Gruenberger T. Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005;189:173-177.
16. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001;193:384-391.
17. Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41-47.
18. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96.
19. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 2004;24:189-199.
20. Jiang W, Zeng ZC, Tang ZY, Fan J, Sun HC, Zhou J, et al. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol 2011;22:1644-1652.
21. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009;33:1247-1254.
22. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934-1940.
23. Suzuki T, Shin BC, Fujikura K, Matsuzaki T, Takata K. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett 1998;425:436-440.
24. Carlson CM, Frandsen JL, Kirchhof N, McIvor RS, Largaespada DA. Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A 2005;102:17059-17064.
25. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 2007;104:14771-14776.
26. Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhaus GJ. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998;68:187-192.
27. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 2011;31:173-187.
28. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995;109:1612-1617.
29. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002;49:604-608.
30. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010;2:419-427.
31. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:44-54.
32. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:14-22.
33. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004;10:1294-1300.
34. Murakami Y, Uemura K, Hayasidani Y, Sudo T, Hashimoto Y, Ohge H, et al. Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci 2009;54:1360-1364.
35. Ellis MC, Cassera MA, Vetto JT, Orloff SL, Hansen PD, Billingsley KG. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. HPB (Oxford) 2011;13:59-63.
36. Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010;10:470-480.
37. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010;28:585-593.
38. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev 2009;23:877-889.
39. Nishikawa Y, Doi Y, Watanabe H, Tokairin T, Omori Y, Su M, et al. Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol 2005;166:1077-1088.